Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 478 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transdermal patch Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

NCT02727205
View directory record Official record
Conditions
Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch
Interventions
Rotigotine Transdermal System
Drug
Lead sponsor
Inflamax Research Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Results available

Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants

NCT02395653
View directory record Official record
Conditions
Pain, Postoperative
Interventions
fentanyl
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Results available

The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.

NCT00315445
View directory record Official record
Conditions
Back Pain
Interventions
Buprenorphine transdermal patch, Placebo oxycodone/acetaminophen tablets, OXY/APAP, Placebo transdermal patch (TDS)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
12
States / cities
Huntsville, Alabama • Phoenix, Arizona • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

NCT00206622
View directory record Official record
Conditions
Hot Flashes
Interventions
Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal), Placebo transdermal
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
45
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 29, 2009 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Not applicable Interventional Results available

A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care for Homeless Smokers

NCT02565381
View directory record Official record
Conditions
Smoking
Interventions
Transdermal nicotine patch, In-person smoking cessation counseling, Contingent financial rewards for smoking abstinence, Text messages to support smoking abstinence
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 3 Interventional

Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee

NCT00488267
View directory record Official record
Conditions
Osteoarthritis
Interventions
ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System), Placebo Matrix/CHADD Patch, Ketoprofen matrix/placebo CHADD Patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Peoria, Arizona • Anaheim, California • Buena Park, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 2 Interventional Results available

Memory Improvement Through Nicotine Dosing (MIND) Study

NCT02720445
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Nicotine Transdermal Patch, Placebo Patch
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
36
States / cities
Scottsdale, Arizona • North Little Rock, Arkansas • Downey, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

NCT06257537
View directory record Official record
Conditions
Osteo Arthritis Knee, Arthritis
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches, SAM Patch
Device · Drug · Other
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Stamford, Connecticut • Trumbull, Connecticut • Dryden, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries

NCT02132247
View directory record Official record
Conditions
Athletic Injuries
Interventions
Diclofenac hydroxyethylpyrrolidine
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
6 Years to 16 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Little Rock, Arkansas • St. Petersburg, Florida • Marietta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Not applicable Interventional

Anesthetics in Rhytidoplasty - A Comparison Study

NCT02410460
View directory record Official record
Conditions
Rhytidoplasty
Interventions
clonidine, glycopyrrolate, propofol, ketamine, marcaine, scopolamine, midazolam, ondansetron, metoclopramide, lidocaine, famotidine, desflurane, sevoflurane
Drug · Device
Lead sponsor
Mercy Facial Plastic Surgery Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

NCT04936984
View directory record Official record
Conditions
Osteoporosis
Interventions
abaloparatide-sMTS (Patheon), abaloparatide-sMTS (Kindeva)
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity

NCT00664755
View directory record Official record
Conditions
Nicotine Dependence
Interventions
varenicline, transdermal nicotine patch
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

NCT01533428
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Pain
Interventions
Capsaicin 8%, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Anniston, Alabama • Fresno, California • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

NCT00314652
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 3, 2006 · Synced Oct 22, 2026, 3:52 AM EDT
Terminated Phase 2 Interventional Results available

Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure

NCT00957034
View directory record Official record
Conditions
Heart Failure
Interventions
placebo, testosterone
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Lakewood, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)

NCT04366726
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
abaloparatide-sMTS
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

NCT01259115
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine transdermal patch, Ketoconazole tablet, Placebo to match ketoconazole tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 54 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Not applicable Interventional Results available

Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers

NCT01259466
View directory record Official record
Conditions
Smoking Cessation, Overweight, Obesity
Interventions
Nicotine patch
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers

NCT01702519
View directory record Official record
Conditions
Smoking
Interventions
nicotine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 20, 2015 · Synced Oct 22, 2026, 3:52 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

NCT04597099
View directory record Official record
Conditions
PCOS, Polycystic Ovary Syndrome
Interventions
Micronized progesterone, Placebo, Flutamide, Estradiol patch
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 4 Interventional Results available

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

NCT03720847
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 2 Interventional Results available

Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes

NCT00960778
View directory record Official record
Conditions
Nicotine Dependence
Interventions
nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol), denicotinized cigarettes (Quest 3 cigarettes)
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

NCT00099242
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Alzheimer Type
Interventions
rivastigmine transdermal patch
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
22
States / cities
Orange, California • San Francisco, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 22, 2026, 3:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotine Treatment of Cognitive Decline in Down Syndrome

NCT01778946
View directory record Official record
Conditions
Down Syndrome, Mild Cognitive Impairment
Interventions
Low Dose Nicotine (7mg), Moderate Dose Nicotine (14mg)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
25 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 22, 2026, 3:52 AM EDT